WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription. “While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free. The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS. |
A vibrant city on ancient Silk RoadMichael Jackson's iconic sequined 'Billie Jean' jacketLeBron James EXPLODES on Lakers coach Darvin Ham for not challenging outPeople have fun during Mid9 people going on trial over an alleged farPacers hit franchise playoff best 22 3Boeser's hat trick helps Canucks rally, push Preds to brink of eliminationMusiala, Wirtz following in footsteps of Messi, ModricBernabeu balancing act for Valverde with Copa del Rey final aheadBrunei welcomes 1st Chinese tourist group in 3 years